We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic
Industry revs up lobbying effort after Biden backs suspension of intellectual property rights
Chief of vaccine maker says relaxing protections ‘will not help’ boost Covid jab supplies
Chief executive says company will boost manufacturing capacity to tackle variants of Covid-19
Rome’s talks with manufacturers come as EU seems to be moving away from AstraZeneca and J&J
Scientists are testing the risks and advantages of offering a different shot for second and third doses
Third jab comes into use as concerns over AstraZeneca side effects investigated
Boris Johnson urges caution as England enters second phase of lockdown easing
Questions mount over whether Soriot’s dash and drive, which enthral investors, have resulted in missteps
New vaccine producers and mRNA technology are shaking up the market
Loss-making US biotech’s fortunes transformed by pandemic as it moves to test booster targeting variant
US biotech is preparing for a clinical trial to gauge effectiveness on 501.V2 strain
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
FT tracker shows rapid growth in doses administered around world — but warnings come of long road ahead
Reductions follow week of clashes between Brussels and AstraZeneca over Covid vaccine supplies
Pharmaceutical industry faces new race as worrying variants emerge
US drugmaker warns current jab is less effective against South Africa variant
Official document suggests enough doses for 500,000 jabs a day by next week
Sandra Gallina denies wrong products have been bought and says member states remain committed to joint action
A total of 17m jabs will be available later this year
Decision follows recommendation from European Medicines Agency amid infections spike
Health systems around world struggle to bring immunisation programmes up to speed
Why it doesn’t pay for pharma companies to profit from the pandemic in the long run.
US agency go-ahead will provide boost to supplies as hospitalisations due to pandemic soar
International Edition
